Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 15, 2021Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyOpen Access

Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAbbie D. LeinoCincinnati Children's Hospital Medical CenterJPJeong Mi ParkUniversity of MichiganAPAmy L. PasternakUniversity of Michigan

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Leino et al. (2021) studied this question.

synapsesocial.com/papers/6a623ea70579a17fd4c94d1ehttps://doi.org/10.1002/phar.2601
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance2011 · 37 citations
  2. 2Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions2014 · 1,353 citations
  3. 3Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients2007 · 50 citations
  4. 4Variability index of tacrolimus serum levels in pediatric liver transplant recipients younger than 12 years: Non‐adherence or risk of non‐adherence?2017 · 21 citations
  5. 5Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients2021 · 15 citations